|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2006-7-31
|
|
pubmed:abstractText |
Acylated and aroylated hydrazinoclozapines are highly potent dopamine D(1) antagonists that show remarkable selectivity over other dopamine receptors. The most potent compound in this series is the 2,6-dimethoxybenzhydrazide 33 with a D(1)K(i) of 1.6 nM and 212-fold selectivity over D(2) receptor.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4543-7
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Hydrazides of clozapine: a new class of D1 dopamine receptor subtype selective antagonists.
|
|
pubmed:affiliation |
Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. thavalakulamgar.sasikumar@spcorp.com
|
|
pubmed:publicationType |
Journal Article
|
